President and CEO of Varian Medical Systems Inc (NYSE:VAR) Dow R Wilson sold 88,766 shares of VAR on 12/18/2017 at an average price of $111 a share. The total sale was $9.9 million.
Varian Medical Systems Inc is engaged in the healthcare sector. It manufactures medical devices for conditions with radiotherapy, radiosurgery, proton therapy and brachytherapy. Varian Medical Systems Inc has a market cap of $10.15 billion; its shares were traded at around $110.78 with a P/E ratio of 41.17 and P/S ratio of 3.65. Varian Medical Systems Inc had annual average EBITDA growth of 4.60% over the past ten years.
CEO Recent Trades:
President and CEO Dow R Wilson sold 88,766 shares of VAR stock on 12/18/2017 at the average price of $111. The price of the stock has decreased by 0.2% since.
Directors and Officers Recent Trades:
EVP and Pres. Oncology Sys. Kolleen T Kennedy sold 2,018 shares of VAR stock on 12/13/2017 at the average price of $111.97. The price of the stock has decreased by 1.06% since.
For the complete insider trading history of VAR, click here
Top Medical Stocks For 2018: Sigma Designs, Inc.(SIGM)
- [By Lisa Levin]
Sigma Designs Inc (NASDAQ: SIGM) shares dropped 30 percent to $5.43. Sigma Designs reported fiscal third-quarter net income of $221,000 on revenue of $62.7 million.
- [By Paul Ausick]
Sigma Designs Inc. (NASDAQ: SIGM) dropped about 34% on Wednesday to post a new 52-week low of $5.20 against a 52-week high of $8.60 and a Tuesday close of $7.75. Volume of about 6.2 million was about 25 times the daily average of around 280,000. The company reported so-so earnings on Tuesday and the stock was downgraded and price targets lowered by several analysts.
- [By Lisa Levin]
Pyxis Tankers Inc. (NYSE: PXS) rose 47.48 percent to $$5.56, after the company announced it has entered into a definitive securities purchase agreement with a group of investors, which will result in gross proceeds of $4.8 million.
Sigma Designs Inc (NASDAQ: SIGM) rose 22.77 percent to $6.88. Silicon Laboratories (NASDAQ: SLAB) announced plans to buy Sigma Designs for $7.05 per share in cash.
Steadymed Ltd (NASDAQ: STDY) rose 19.35 percent to $3.70, after the company reported that no clinical trials were required for Trevyent and that the FDA had agreed to the pathway for the drug candidate's NDA resubmission.
Iteris, Inc. (NASDAQ: ITI) rose 15.73 percent to $7.06. Earlier in the week, Zacks Investment Research had upgraded the company from "Sell" to "Hold".
Science Applications International Corp (NYSE: SAIC) rose 13.71 percent to $85.77 as the company reported better-than-expected earnings for its third quarter.
Technical Communications Corporation (NASDAQ: TCCO) rose 12.41 percent to $6.07, after having risen sharply in pre-marketing trading.
Radius Health, Inc. (NASDAQ: RDUS) rose 12.41 percent to $30.81 after the company provided an update on data from the Phase 1 005 clinical study of elacestrant in patients with estrogen receptor positive breast cancer during the 2017 San Antonio Breast Cancer Symposium.
ForeScout Technologies, Inc. (NASDAQ: FSCT) rose 12.32 percent to $25.80 after the company reported its third quarter financial results.
Prana Biotechnology Limited (NASDAQ: PRAN) rose 11.36 percent to $3.43, as the company announced a research collaboration with Takeda Pharmaceuticals to study the ability of movement disorders compound, PBT434 to slow or prevent neurodegeneration of the gastrointestinal system.
Catalyst Biosciences, Inc. (NASDAQ: CBIO) rose 10.49 percent to $7.90 as the company announced the appointment of Arwa Shurrab and Jamie Ellen Siegel in its clinical hemophilia
Top Medical Stocks For 2018: Banco Santander, S.A.(SAN)
- [By WWW.THESTREET.COM]
Banco Santander (SAN) : “I prefer Barclays (BCS) , but let’s wait and see what the other banks have to say”
ProLogis (PLD) : “I am not a fan of that group right now, but that one is best of breed.”
Top Medical Stocks For 2018: Matador Resources Company(MTDR)
- [By Ben Levisohn]
Our peer group is up an average of 46% over the past 4 weeks in response to a 30% rebound in the 12-month strip NYMEX oil price. Some of the largest gainers include Hold and Sell rated stocks that we would not chase such asDenbury Resources (Sell, +138%), Halcon Resources (HK) (Sell, +147%), Jones Energy (JONE) (Hold, +166%), Rex Energy (REXX) (Sell, +60%), Sanchez Energy (SN) (Hold, +93%), Ultra Petroleum (UPL) (Sell, +61%), andWhiting Petroleum (Hold, +103%), which have outperformed the E&P Index (+32%) over the same time period. Balance sheets and/or well level returns remain challenged for these companies despite improved oil prices. While we believe oil markets should re-balance over the next 12 to 15 months, the recent recovery to $40 could reverse during 2Q16 as bloated inventories continue to rise, new volumes from Iran pressure an oversupplied market, and a highly anticipated decline in non-OPEC supply (especially in the U.S.), is not as steep as expected. The risk of an oil price retracement, which would significantly pressure the recent out-performers, outweighs the upside in these stocks, in our view. However, we are raising our target prices on Buy ratedAnadarko Petroleum ($54 from $48), Concho Resources (CXO) ($120 from $109), Matador Resources (MTDR) ($22 from $21),Noble Energy (NBL) ($40 from $34), SM Energy (SM) ($22 from $15), Rice Energy ($14 from $12), Pioneer Natural Resources (PXD) ($155 from $135),Continental Resources ($32 from $28), and Parsley Energy (PE) ($24 from $23). We believe our Buy-rated stocks are better positioned to weather challenging oil markets.
- [By Ezra Schwarzbaum]
But despite positioning that would thrash other similar companies, Resolute fought through thanks to significant and efficient productivity in its Delaware Basin assets. Wangler believes the strengthening of previous concern areas will make the company a solid investment.
Matador Resources Co (NYSE: MTDR), $32 Price Target
Matador has grown its reserves throughout the commodity cycle, as well as its production and cash flow. Haas also likes the company’s history of identifying and acquiring acreage early and cheaply. Much of the analyst’s positive outlook is derived from Matador’s successful monetization of midstream assets and pattern of reinvestment.
Top Medical Stocks For 2018: SPDR S&P Biotech ETF (XBI)
- [By ]
After sneaking lower to begin the new trading week, the SPDR S&P Biotech ETF (NYSE:XBI) and the iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) were each approaching important support levels.
- [By WWW.KIPLINGER.COM]
Theres been follow-up, too: Valeant Pharmaceuticals Intl Inc (VRX) had to face the Senate in April for aggressively hiking prices on its drugs. Now Mylan NV (MYL) is answering to the government soon after a story showed that EpiPen prices have rocketed 400% since 2008 with no significant improvements to the treatment. This scandal, too, is rocking biotechs including (Link]recommendation SPDR S&P Biotech ETF (XBI).
- [By ]
And while the big drug companies will experience a significant adjustment, biotech companies, with their focus on long term results and outright cures in some cases, are probably poised to perform. The best way to get invested would be with the Biotech Spider ETF (NYSE: XBI).
- [By ]
The SPDR S&P Biotech ETF (NYSE:XBI) and the iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) were each approaching important support levels back in mid-November.
Top Medical Stocks For 2018: Samsung Electronics Co. Ltd. (SSNLF)
- [By SEEKINGALPHA.COM]
The company is partnering with Chinese company OXi Technology (in which it also made a strategic investment) for developing fingerprint sensor under glass and in the bezel of smartphones. Its fingerprint sensor business received a boost from the Samsung (OTC:SSNLF) S8 and S8+ design wins (as well as Sharp’s (OTCPK:SHCAF) Aquos R and ZTE ZMax Pro).
- [By SEEKINGALPHA.COM]
The rate of change in the semiconductor industry is very rapid as implied by the Moore’s law. Hence, it is a very capital-intensive and research-driven industry. The cost of opening a new fab (semiconductor fabrication plant) would cost billions of dollars and roughly 10% of sales for an integrated semiconductor company like Intel (NASDAQ:INTC) and Samsung (OTC:SSNLF) is plowed back into R&D, i.e., billions of dollars annually. Hence, a threat from a new entrant is highly unlikely in the semiconductor industry, at least as of now.
- [By Anders Bylund, Chuck Saletta, and Brian Feroldi]
According to comments by Universal Display CEO Steve Abramson, Samsung (NASDAQOTH:SSNLF) is pouring $9 billion into building OLED production facilities this year. LG Display (NYSE:LPL) expects more than half of its 2020 revenues to come from OLED panels. The OLED TV market is expected to grow sixfold in the next four years, and the lighting panel market is only just getting started.
- [By Ashraf Eassa]
As part of this discussion, he took the time to explain how the technology that Intel calls 14 nanometers is more like what its competitors — Samsung (NASDAQOTH:SSNLF) and Taiwan Semiconductor Manufacturing Co.(NYSE:TSM) — call 10 nanometers (smaller is generally believed to be better).
- [By Peter Graham]
A long term performance chart shows shares of mid cap BlackBerry Ltd drifting lower for the past 1 1/2 years whilethe performance of Samsung Electronics (OTCMKTS: SSNLF) and Apple Inc (NASDAQ: AAPL) have beenrising for at least thepast several months: